Thomas Ciulla - Jan 3, 2024 Form 3 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Thomas Ciulla
Stock symbol
VRDN
Transactions as of
Jan 3, 2024
Transactions value $
$0
Form type
3
Date filed
1/12/2024, 04:31 PM
Previous filing
Jan 20, 2023
Next filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VRDN Common Stock 762 Jan 3, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VRDN Stock Option (Right to Buy) Jan 3, 2024 Common Stock 250K $33.06 Direct F1
holding VRDN Stock Option (Right to Buy) Jan 3, 2024 Common Stock 50K $28.22 Direct F2
holding VRDN Stock Option (Right to Buy) Jan 3, 2024 Common Stock 270K $13.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on February 17, 2024, with the remaining vesting in approximately equal monthly installments through February 17, 2027, subject to the Reporting Person's continued service to the Issuer.
F2 This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 8,333 of which have vested, with the remaining vesting in approximately equal monthly installments through April 25, 2027, subject to the Reporting Person's continued service to the Issuer.
F3 This option represents a right to purchase a total of 270,000 shares of the Issuer's common stock, 11,250 of which have vested, with the remaining vesting in approximately equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to the Issuer.